Stay updated on Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe ClinicalTrials.gov page now displays site revision v3.8.0 instead of v3.7.2. The study record history itself is unchanged.SummaryDifference0.1%

- Check19 days agoChange DetectedA banner announces that NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference0.9%

- Check26 days agoChange DetectedThe website footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check33 days agoChange DetectedThe footer now identifies the site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.1%

- Check54 days agoChange DetectedThe record history now includes a new revision (v3.7.0) and the previous revision (v3.6.6) is removed, indicating an update to the study record’s metadata.SummaryDifference0.1%

- Check75 days agoChange DetectedA new revision line appears in the study record history, updating the version from v3.6.5 to v3.6.6. This reflects a platform release update applied to the page rather than changes to the study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial page.